trials comparing the GnRH antagonist degarelix with GnRH agonists favored the former in terms of cardiovascular safety. 8 Notably, the incidence of cardiovascular events was strongly reduced in the subgroup comprising patients with preexisting
Search Results
Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian
Venkata K. Pokuri, Houman Nourkeyhani, Bodie Betsy, Laurie Herbst, Marcus Sikorski, Edward Spangenthal, Andrew Fabiano, and Saby George
dose of degarelix (a GnRH antagonist) was then administered subcutaneously. Ketoconazole was discontinued and hydrocortisone was tapered. He received another dose of degarelix (80 mg subcutaneously) 4 weeks later. His motor strength improved in
Yan Hiu Athena Lee, Jiandong Zhou, Jeremy Man Ho Hui, Xuejin Liu, Teddy Tai Loy Lee, Kyle Hui, Jeffrey Shi Kai Chan, Abraham Ka Chung Wai, Wing Tak Wong, Tong Liu, Kenrick Ng, Sharen Lee, Edward Christopher Dee, Qingpeng Zhang, and Gary Tse
analysis by the subgroup of ADT (GnRH antagonists vs non-ADT: HR, 0.71; 95% CI, 0.39–1.30; P =.2670; and GnRH agonists vs non-ADT: HR, 0.76; 95% CI, 0.58–1.00; P =.0504). Use of ADT was not associated with significantly different risk of all
